TO THE EDITOR
Pure red cell aplasia (PRCA) develops in approximately 6% of chronic lymphocytic leukemia (CLL) patients, most often in the course of the disease but also at presentation. 1 We report a patient who pressented with PRCA as the first manifestation of CLL, which was refractory to sequential treatments with steroids, i.v. immunoglobulins, cyclosporin A and alkylating agents and eventually responded to a combination of fludarabine followed by cyclosporin A and erythropoietin (Epo).
A 47-year-old previously healthy patient presented with fatigue gradually developing over 6 weeks. Physical examination revealed pallor and small lymph nodes in the left supraclavicular area. The spleen and liver were not enlarged. Complete blood count (CBC) revealed Hb 6.5 g/dl (Hct 19%, MCV 97), WBC 15.3 × 10 9 /l (75% lymphocytes), plt 262 × 10 9 /l. Blood smear showed lymphocytosis with small mature lymphocytes and Gumprecht cells. Reticulocyte count was 0%. Bone marrow (BM) aspiration and biopsy showed hypercellular material with focal and interstitial infiltration by small mature lymphocytes. The myeloid and megakaryocytic lineages were preserved but only occasional large proerythroblasts with no maturation to normoblasts were seen. This morphological finding could be compatible with parvovirus B19 infection but repeated negative serological test and negative PCR test ruled this out. Analysis of in vitro cultures of BM and peripheral blood cells showed a severely reduced number of BFU-E colonies. Immunophenotyping of peripheral blood mononuclear cells revealed that 80% were CD5 +
CD20
+ and 13% were T cells with a CD4/CD8 ratio of 1.1. Serum biochemistry tests, immunoglobulin, folic acid and vitamin B12 levels were within normal limits. Coombs' test was negative and there were no signs of hemolysis. A diagnosis of B-CLL Rai stage I, Binet A accompanied with PRCA was established. The patient was treated with prednisone (60 mg/day) and cyclosporin A (200 mg/day for 10 weeks then 300 mg/day for an additional 4 weeks) but did not respond. He remained transfusion dependent; reticulocyte count was 0%. During the following 6 months the patient did not respond to successive trials of i.v. gammaglobulins, Epo, chemotherapy with cyclophosphamide and vincristine and then with continuous oral chlorambucil and prednisone. We then decided to treat the patient with fludarabine (50 mg/day × 5 days). At the end of two courses CBC revealed Hb 8.0 g/dl, WBC 3.7 × 10 9 /1 (52% lymphocytes), plt 126 × 10 9 /l, reticulocytes 0%. Fludarabine was discontinued because there was no response of PRCA but the patient became severely lymphopenic with a T cell count Ͻ0.3 × 10 9 /l. We therefore decided 2 months after the initiation of fludarabine treatment to try again with cyclospo- rin A (300 mg/day) and prednisone (20 mg/day). Three weeks later, BM aspiration showed for the first time since presentation, maturation to normoblasts, although the BM was still infiltrated with CLL. The patient, who had received 36 units of packed cells by this time, became transfusion free and Hb rose slowly to 10 g/dl and reticulocytes to 1.2%. During the following weeks the Hb level remained stable. A repeated BM examination showed an increase in immature normoblasts. Epo 10 000 units s.c. three times/week was given. The combination of cyclosporin A 300 mg/day and Epo induced a clear and stable response. The last blood count 11 months after diagnosis showed Hb 13.5 g/dl, Hct 42%, reticulocytes 2%, WBC 7000 (54% lymphocytes), plt 220 × 10 9 /l ( Figure 1 ). PRCA is a rare complication of CLL. 1 It is most commonly associated with B CLL but has also been reported in T cell CLL and other lymphoproliferative disorders. Suppressor/ cytotoxic T cells have been shown to exert a suppressive effect on erythropoiesis in CLL.
2 Therefore, treatment of this complication usually relies on immunosuppressive drugs. Cyclosporin A and steroids emerged as the treatment of choice for PRCA associated with CLL. Response to this regimen usually occurs without a reduction in tumor mass and time to response is short (2-3 weeks). 3 Alkylating agent chemotherapy can also induce remission of PRCA but not until a substantial decrease in tumor mass occurs, which takes a few months of treatment. 3 Cyclosporin A was found to be effective in chemotherapy-resistant PRCA as well. Fludarabine has been proven to be an effective agent for treating CLL patients who failed conventional chemotherapy and its role in front-line therapy is under intensive investigation. Autoimmune phenomena may appear or exacerbate during fludarabine therapy and there are some reports of PRCA developing during therapy with this agent. 4 Antithymocyte globulin (ATG) has been used successfully in a few cases of CLL-associated PRCA. 5 Its effect is probably mediated by elimination of the T cell population that suppresses erythropoiesis. Fludarabine also has a strong Tdepleting effect but its effect in PRCA is unknown. One case of CLL-associated PRCA responded to fludarabine 6 and another case responded to cyclosporin A and Epo without fludarabine. 7 Our patient was resistant to cyclosporin A, steroids, Epo and alkylating agents. We chose fludarabine because of its effect in controlling the tumor mass. The PRCA did not respond, but the patient became severely lymphopenic. The reintroduction of cyclosporin A led to a rapid response with appearance of reticulocytes and no more requirement for blood transfusion. This course is typical of response to cyclosporin A but was not achieved when used the first time in our patient. We speculate that the reduction in the tumor mass and the T cell population caused by fludarabine, although not sufficient to induce remission of PRCA by itself, allowed a successful response to cyclosporin A. Then when normoblasts regenerated, the addition of Epo enhanced the maturation of the erythropoietic line. We suggest that the Hemoglobin level and sequential treatment in a CLL case complicated by PRCA.
combination of fludarabine followed by cyclosporin A and Epo may be used in the rare refractory cases of CLL complicated by PRCA. 
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